Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bristol Myers Squibb (NYSE: BMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings help investors understand how a global biopharmaceutical company in pharmaceutical preparation manufacturing manages its capital structure, reports financial results and communicates material events.
Recent Form 8-K filings from Bristol-Myers Squibb Company cover a range of topics. Some 8-Ks furnish quarterly earnings press releases and accompanying investor presentations, giving detail on financial performance and operating initiatives. Others describe the issuance of euro-denominated senior notes by a wholly owned Irish subsidiary, fully and unconditionally guaranteed by the company, including the terms of the notes, the governing indenture and the intended use of proceeds for tender offers and other corporate purposes. Additional 8-Ks outline cash tender offers for existing notes, early participation results, accepted amounts and pricing terms.
Filings also document corporate governance and executive matters, such as the departure of certain senior executives and related compensation arrangements, along with regular disclosures of dividend declarations. Regulation FD disclosures appear when the company posts investor presentations or updates on its website, and when it furnishes investor decks or webcasts tied to earnings calls and capital markets events.
On Stock Titan, these documents are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the significance of complex filings, from debt offerings and tender offers to earnings releases and Regulation FD presentations. Users can quickly see what each filing covers, identify items related to capital markets activity, dividends or governance, and then drill into the full text when deeper analysis is needed. This page is a practical starting point for reviewing Bristol Myers Squibb’s official disclosures that may affect BMY stock and related securities, including its listed notes and Celgene contingent value rights.
Bristol Myers Squibb executive Benjamin Hickey reported routine equity compensation activity. On February 1, 2026, 10,079 restricted stock units vested, each converting into one share of common stock at an exercise price of $0.
To cover taxes on the vesting, 3,810 common shares were withheld at a price of $55.05 per share. After these transactions, Hickey directly owned 15,058 shares of Bristol Myers Squibb common stock and 10,079 restricted stock units remained outstanding, scheduled to vest in equal annual installments beginning February 1, 2025.
Bristol Myers Squibb director Phyllis R. Yale received 3,996.367 Deferred Share Units on February 1, 2026 at a reference price of $55.05 per unit. These derivative awards increase her holdings of Deferred Share Units to 43,326.695, all held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when she ceases to be a director or at a future date she previously specified, and reflect deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Karen H. Vousden reported an award of derivative securities tied to company stock. On February 1, 2026, she acquired 3,996.367 Deferred Share Units at $55.05 each, bringing her total to 41,069.315 Deferred Share Units, held directly.
Each Deferred Share Unit converts into one share of Bristol Myers Squibb common stock upon settlement. These units become settleable when she ceases to be a director or at a future date she previously selected. The total includes deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II reported an automatic grant of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. After this award, he beneficially owns 67,882.504 Deferred Share Units in total.
Each Deferred Share Unit converts into one share of common stock when settled. These units become settleable when he ceases to be a director or on a future date he previously selected, and the total includes deferred compensation and reinvested dividends under the company’s deferred compensation plan for non-employee directors.
Bristol Myers Squibb director Derica W. Rice reported an award of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. This increased his holdings of Deferred Share Units to 39,324.809, which track common stock and are settled in shares later.
Each Deferred Share Unit converts into one share of common stock when he leaves the board or on a future date he previously selected. The holdings also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Paula A. Price reported receiving 3,996.367 Deferred Share Units on February 1, 2026 at an indicated value of $55.05 per unit. Following this award, she beneficially owns 25,498.163 Deferred Share Units, held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when Price ceases to be a director or at a future date she previously specified, and include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen reported an acquisition of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. Following this transaction, he beneficially owns 14,979.689 Deferred Share Units directly.
Each Deferred Share Unit will convert into one share of common stock upon settlement, which occurs when McMullen ceases to be a director or at a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Manuel Hidalgo Medina reported an award of 3,996.367 Deferred Share Units on common stock, effective February 1, 2026, at a reference price of $55.05 per unit. Following this grant, he holds 22,763.938 Deferred Share Units in total, all reported as directly owned.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. According to the disclosure, these units become settleable when he ceases to be a director or on a future date he previously specified. The total also reflects deferred compensation and dividends that have been reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Julia Haller reported a grant of deferred share units. On 02/01/2026 she acquired 3,996.367 deferred share units at $55.05 each, bringing her total to 37,903.154 derivative securities held directly. Each unit will convert into one share of common stock when she ceases to be a director or at a future date she previously selected.
The holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors, showing this is board compensation structured in stock-linked form rather than a cash payment.
Bristol Myers Squibb director Deepak Bhatt reported an award of 3,996.367 Deferred Share Units on February 1, 2026, at a reference price of $55.05 per unit. After this transaction, he beneficially owned 19,241.818 Deferred Share Units held directly.
Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. These units become settleable when Bhatt ceases to be a director or at a future date he previously specified, and the total includes deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.